The filing content is cut off before the financial statements and MD&A sections. However, the cover page and forward-looking statements section contain substantive disclosure content (share count, company details, filing period, and forward-looking risk factors). Let me assess whether the substantive content meets the 150-word threshold. The substantive content includes: the quarterly period ended September 30, 2026; 36,119,043 shares outstanding as of November 9, 2026; Delaware incorporation; address at 3940 Trust Way, Hayward, California 94545; smaller reporting company and non-accelerated filer status; NASDAQ:BNTC listing; and the extensive list of risk factors related to BB-301 development, ddRNAi technology, clinical trials, regulatory filings, financing needs, and other operational matters. This clearly exceeds 150 words of substantive content. However, the financial statements themselves are cut off, leaving no actual financial figures to report. I can only report what the filing contains.

Benitec Biopharma Inc. filed its quarterly report on Form 10-Q with the SEC on November 13, 2026, covering the fiscal quarter ended September 30, 2026, with financial statements provided on an unaudited basis.

Key Highlights

  • Shares outstanding: The company reported 36,119,043 shares of common stock outstanding as of the close of business on November 9, 2026.
  • Filer status: The registrant is classified as a non-accelerated filer and a smaller reporting company, according to the filing.
  • Exchange listing: Common stock, par value $0.0001, is listed on NASDAQ:BNTC under the Nasdaq Stock Market LLC.
  • Principal address: The company disclosed its principal executive offices at 3940 Trust Way, Hayward, California 94545.
  • Lead program: The filing identifies BB-301 as the company's primary product candidate under development, citing ddRNAi (DNA-directed RNA interference) technology as its platform.
  • Not a shell company: The registrant indicated it is not a shell company as defined under Rule 12b-2 of the Exchange Act.

Benitec Biopharma's September 2026 Quarter Filing: What the Report Contains

Benitec Biopharma Inc. (NASDAQ:BNTC), a Delaware-incorporated biopharmaceutical company headquartered in Hayward, California, submitted its quarterly report for the period ended September 30, 2026. The filing carries Commission File Number 001-39267 and was submitted under Section 13 or 15(d) of the Securities Exchange Act of 1934. As of November 9, 2026, the company reported 36,119,043 shares of common stock outstanding.

The report is structured to include unaudited consolidated financial statements, management's discussion and analysis, and disclosures on market risk and internal controls, according to the filing's index. The financial statements section, as listed in the index, covers consolidated balance sheets, statements of operations and comprehensive loss, statements of stockholders' equity, and statements of cash flows, along with accompanying notes.

The filing contains an extensive set of forward-looking statements, which the company states "are subject to a number of risks and uncertainties, many of which are beyond our control." Among the risks identified are the development and potential commercialization of BB-301, clinical trial timing, regulatory outcomes, financing needs, and the ability to retain key personnel. The company cautions that actual results "may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements." The company further states it "undertake[s] no obligation to revise or update any forward-looking statements" except as required by law.

What Was Disclosed

Benitec Biopharma filed its unaudited quarterly report for the period ended September 30, 2026, disclosing 36,119,043 shares outstanding as of November 9, 2026, its smaller reporting company and non-accelerated filer status, and its continued focus on BB-301 and ddRNAi platform development.